Milestones
Since 1983, we have imagined a healthier, better world, believing that together we can invest to make a difference in people’s lives. In 2018, we celebrated our 35 years of commitment.
)
1983
Wolfgang Marguerre establishes Octapharma with a single idea: people with haemophilia deserve access to better products.
1985
The first factor VIII medicine, octavi®, is launched.
1990
Opens first state-of-the-art manufacturing site, acquired from Schwab in Vienna, Austria.
1992
Establishes laboratory in Frankfurt for validation and documentation of virus inactivation methods.
1999
Acquires second manufacturing site from Aventis in Lingolsheim, France, to increase capacity.
2002
Acquires third manufacturing site from Biovitrum in Stockholm, Sweden, to increase product portfolio.
2003
Expands into US market with FDA registration of octagam®.
2006
Acquires five plasma donation centres in Germany from Deutsche Gesellschaft für Humanplasma.
2007
Octapharma Plasma Inc. founded in the US to operate our own plasma donation centres.
2008
Acquires fourth state-of-the-art manufacturing site from German Red Cross in Springe, Hanover, Germany.
2012
Opens the Institute for Recombinant Protein Research & Development in Heidelberg, Germany, to further invest in innovative therapies.
2014
European Medicines Agency (EMA) approves our first recombinant product for haemophilia A patients, Nuwiq®.
2015
FDA approves Nuwiq® for haemophilia A patients in the USA.
2016
panzyga® receives regulatory approval in Canada and the EU for primary immunodeficiency syndromes and primary immune thrombocytopenia.
2017
Fibryga® receives marketing authorization for congenital fibrinogen deficiency in 16 EU countries, the US and Canada.
2018
Octapharma announces promising pre-clinical data for SubQ-8, our recombinant FVIII in development for subcutaneous administration.
2019
Our human fibrinogen concentrates receives European label extension to treat acquired fibrinogen deficiency.